A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Advanced Solid Tumors
DRUG: BMS-986482|DRUG: Nivolumab and rHuPH20|DRUG: Nivolumab/relatlimab/rHuPH20|DRUG: Bevacizumab
Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0), Up to 135 days post last treatment visit|Number of participants with Serious AEs (SAEs) as assessed by NCI-CTCAE v5.0, Up to 135 days post last treatment visit|Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria as assessed by NCI-CTCAE v5.0, Up to Day 28|Number of participants with AEs leading to discontinuation as assessed by NCI-CTCAE v5.0, Up to 135 days post last treatment visit|Number of deaths as assessed by NCI-CTCAE v5.0, Through study completion (approximately 5 years)
Concentration at the end of infusion (Cmax), Up to 135 days post last treatment visit|Time of maximum observed concentration (Tmax), Up to 135 days post last treatment visit|Area under the concentration-time curve in one dosing interval (AUC(TAU)), Up to 135 days post last treatment visit|Overall Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as assessed by Investigator, Up to 135 days post last treatment visit
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.